Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
Johnson & Johnson and Pfizer have distinct revenue generation strategies. JNJ primarily earns money through the development and sale of pharmaceuticals and medical technology products on a global scale. Meanwhile, Pfizer focuses on the production and distribution of prescription medicines and vaccines worldwide.
Over the past eight quarters, it's worth noting that revenue drops are not unusual due to seasonal factors. Both companies experience temporary declines in sales as patients tend to buy more prescriptions towards the end of the year when deductibles are met. However, this seasonality highlights the importance of comparing each quarter to its prior-year counterpart for a more accurate assessment.
A notable point is that JNJ reported positive gains in Q3 2026 compared to the same period in 2025. On the other hand, Pfizer experienced a slight decline in sales during Q3 2026 when compared to the same quarter of the previous year, which warrants investor attention.
Additionally, JNJ showcases less fluctuation in revenue due to its diverse portfolio of 28 products and platforms, each generating over $1 billion in annual sales. Conversely, Pfizer is currently working to recover from the impact of the COVID-19 pandemic, with fewer people receiving the COVID vaccine as the pandemic wanes.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.